Targeting the Immune System: How Checkpoint Inhibitors Changed the Prognosis for Advanced Melanoma

Abstract

Melanoma is a type of aggressive skin cancer that can become very difficult to treat, once it spreads beyond the original site. Surgery is the key to treat melanoma in its earlier stages, such as localized melanoma, and the melanoma has great potential to be successfully removed. On the other hand, once melanoma becomes advanced and enters the metastatic stage, it has historically resulted in limited treatment options as well as poor outcomes. This analysis combines findings from existing research and clinical trials to investigate how immune checkpoint inhibitors can be used for treating and early detection of advanced melanoma. Before the development of immune checkpoint inhibitors, existing treatments included chemotherapy and cytokine-based immunotherapies. Unfortunately, these past treatments produced limited responses and a small chance of leading to durable disease control. First, this paper explains the essential biological characteristics of melanoma, including its high number of mutations and its ability to evade the immune system, which contributes to melanoma progression. The next topic it elaborates on is how checkpoint inhibitors target two pathways that normally limit T-cell activity, which are PD-1 and CTLA-4. By applying checkpoint inhibitors, new drugs such as nivolumab, ipilimumab, and pembrolizumab, improves T-cells' ability to identify and target melanoma cells. Clinical evidence from major trials of ipilimumab, pembrolizumab, and nivolumab, shows improvements in overall survival, response rates, and long-term disease control compared with earlier treatments. While checkpoint inhibitors do not work for every patient and can cause significant immune-related side effects, they have made it possible for a large percentage of patients to survive from advanced melanoma.